Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01590407 | First in Human Study of ALS-002200; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1 | PHASE1 | COMPLETED | 71 | — | — | Dec 31, 2011 | Feb 28, 2013 | Oct 31, 2017 | 4 | France, Moldova +1 |
data points measured include patient reported adverse events, physical exams, vital signs, 12-lead ECGs and clinical lab results
| Arm | Type | Description |
|---|---|---|
| ALS-002200 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ALS-002200 | DRUG | ALS-002200 |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * Subject has provided written consent. * In the investigator's opinion, the subject is able to understand and comply with protocol requirements, instructions, and protocol stated restrictions and is likely to complete the study as planned. * Subject is in good health as deemed ...